R

Recursion

Data-driven drug discovery platform leveraging datasets

Principal AI Researcher

Full-TimeUpdated
No salary listed
Expert
PhD
Remote in USA
Remote
AI & Machine LearningAI Research

About the job

Requirements
  • A PhD in machine learning, natural language processing, or computer vision, or equivalent practical experience.
  • Passion for real-world applications and impact.
  • Strong verbal and written communication skills.
  • At least 10 years of frontier artificial intelligence research experience.
  • Experience with large datasets and cross-functional artificial intelligence projects.
Responsibilities
  • Join a cross-functional team of scientists, engineers, and drug discovery experts to advance biomedical discovery.
  • Advance frontier research and end-to-end applications across discovery, design, and translation.
Desired Qualifications
  • Experience in biomedicine and drug discovery is a plus.

About the company

Recursion accelerates drug discovery by combining hardware, software, and large biological data to build data-driven workflows. It runs thousands of wet-lab experiments weekly to profile genes and compounds across many cell types, feeding results into its high-power BioHive 1 computer to uncover billions of gene–compound relationships. This integration of vast datasets, high-throughput experiments, and specialized computing enables rapid generation of actionable drug candidates, set within a model that emphasizes strategic partnerships with pharma companies, research institutions, and healthcare providers. The goal is to decode biology at scale and translate discoveries into new medicines that improve patient lives through collaboration and commercialization.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Salt Lake City, UT

Founded

2013

Get referred to Recursion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 Genentech milestone added $3 million and lifted total collaboration payments to $216 million.
  • Recursion cut 2026 cash OpEx guidance to $375 million, extending runway into early 2028.
  • REC-7735 earned IND clearance in Q2 2026, with Phase 1/2 starting in 2H26.

What critics are saying

  • Q2 2026 revenue fell 60% to $7.67 million, exposing partnership volatility.
  • Industry Office SLC landlord litigation from 2023 remains in discovery, risking cash leakage.
  • Any REC-4881 or REC-7735 failure would crush the platform narrative and financing access.

What makes Recursion unique

  • Recursion OS pairs 50-petabyte datasets with BioHive 1 and weekly wet-lab automation.
  • Roche-Genentech validated Recursion’s first neuroscience target in August 2026, proving platform utility.
  • REC-4881 showed 43% median polyp-burden reduction in FAP after three months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus
  • Company Equity
  • Hybrid Work Options

Company News

Yahoo Finance
Nov 2nd, 2026
Recursion extends cash runway into 2029, Sanofi opts first candidate, REC-4881 data impress

Recursion (Nasdaq: RXRX) reported third-quarter 2026 results, extending its expected cash runway into 2029. The runway includes proceeds from an October 2026 follow-on offering. It reiterated 2026 cash operating expense guidance of less than $375 million, and guided to less than $360 million for 2027. New Phase 2 data for REC-4881 in familial adenomatous polyposis showed 87% of patients (13 of 15) had lower total polyp burden after 12 weeks. Median reduction was 47%. The company expects to start a registrational trial in the second half of 2027, pending FDA discussions. Sanofi optioned the first development candidate from their collaboration, triggering a $10 million milestone payment. Recursion may earn more than $300 million in further milestones. Fred Hassan becomes chair of the board on October 31, 2026.

Benzinga
Oct 15th, 2026
Recursion raises $200M, reports 47% polyp reduction in FAP trial and Sanofi option

Recursion (NASDAQ: RXRX) announced a $200 million underwritten offering of common stock. Investors include Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The company expects its cash to last into 2029. The company also updated trial data for REC-4881 in familial adenomatous polyposis. After 12 weeks of treatment, patients had a 47% median reduction in polyp burden, and 85% stayed below baseline 12 weeks after stopping. It aims to start a registrational trial in the second half of 2027, pending talks with the FDA. Sanofi optioned the first development candidate from its collaboration with Recursion, triggering a $10 million milestone payment. Total upfront and milestone payments now stand at $144 million.

Yahoo Finance
Oct 9th, 2026
Recursion Pharmaceuticals burns through cash with $557M reserves lasting until early 2028

Recursion Pharmaceuticals held $557 million in cash at the end of Q2 2026, whilst operations consumed about $0.4 billion over the past twelve months. The biotech company has lowered its 2026 cash spending forecast to $375 million, nearly 40% below 2024 levels, attributing the reduction to greater efficiency. Revenue fell 61.8% year-on-year in the latest quarter and covers roughly a tenth of the company's $0.5 billion operating loss. Management expects cash reserves to last through early 2028. The stock trades at 42.2 times sales, compared to 3.1 for the S&P 500, and has fallen 23% over the past twelve months. A collaboration with Roche-Genentech has generated over $260 million in upfront and milestone payments.

Yahoo Finance
Aug 6th, 2026
Recursion Pharmaceuticals shares fall 4.2% as Q2 revenue drops 60% to $7.67M

Recursion Pharmaceuticals reported a second-quarter loss of 25 cents per share, worse than the estimated 23-cent loss. This compares to a 41-cent loss in the year-ago quarter. Total revenues fell 60% year-over-year to $7.67 million, missing the $14 million estimate. The decline stemmed from lower collaboration revenues with Roche and Genentech following completion of certain project phases. Research and development expenses decreased 30% to $89.6 million, reflecting lower platform costs and improved efficiency. General and administrative expenses fell 11% to $41.5 million. The company held $556.8 million in cash as of 30 June, down from $665.2 million at quarter-end March. Recursion expects current cash reserves to fund operations into early 2028. Shares dropped 4.2% on Wednesday following the results.

Yahoo Finance
Aug 5th, 2026
Recursion cuts 2026 cash guidance to $375M, targeting FAP data in November

Recursion Pharmaceuticals reported Q2 2026 results, highlighting its AI-driven drug discovery platform's progress. The company lowered full-year 2026 cash operating expense guidance to $375 million, nearly 40% below 2024 levels. Recursion's collaboration with Roche-Genentech identified a previously unexplored neuroscience target, triggering part of $260 million in milestone payments. The platform can move from target to candidate in 1.5 years using approximately 330 compounds, versus industry benchmarks of 4 years and 2,500 compounds. The company holds approximately $557 million in cash, providing runway through early 2028. Phase II data for REC-4881 in FAP will be presented in November, with Phase I trial for REC-7735 expected later this year. Recursion appointed a new Chief AI Officer and Head of Drug Design to strengthen its AI capabilities.